Use of Estimates	9 Months Ended
Sep. 30, 2011
Use of Estimates [Abstract]
USE OF ESTIMATES	2. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements and accrued expenses. Actual results could differ from these estimates. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, the Company deemed it probable that it would subsequently receive PMA approval from the FDA for the MelaFind^® PMA application. Accordingly, $1,889 in non-cash compensation expense was recorded as of September 30, 2011 representing options on which the performance vesting milestone is related to FDA approval. Those options remain as unvested on all option tables in this report on Form 10-Q, as vesting took place at the time approval was received.

2. USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements and accrued expenses. Actual results could differ from these estimates.

With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, the Company deemed it probable that it would subsequently receive PMA approval from the FDA for the MelaFind^® PMA application. Accordingly, $1,889 in non-cash compensation expense was recorded as of September 30, 2011 representing options on which the performance vesting milestone is related to FDA approval. Those options remain as unvested on all option tables in this report on Form 10-Q, as vesting took place at the time approval was received.